PURPOSE: The kalifilcon A daily disposable toric CL (INFUSE for Astigmatism [IfA]) is designed to provide clear, stable vision and support ocular surface homeostasis for comfortable wear. This real-world evaluation assessed patient satisfaction and experience with the IfA CL.

METHODS: Astigmatic patients aged ≥18 years (whether new or existing CL wearers) were invited by their eye care practitioners (ECPs) to be fitted with IfA CLs and trial them for a 5-day period. Participants then completed an online survey about their experience, with at least 60% of responses validated through follow-up phone calls. A two-sided asymptotic binomial test assessed whether more than 50% of respondents provided favorable ratings for key attributes.

RESULTS: A total of 208 participants completed the survey (71.2% female, mean age 38.5 years). Of these, 57.2% were current contact lens wearers, 40.9% primarily wore eyeglasses, and 1.9% used no prior vision correction. Most participants (84.1%) reported wearing the IfA lens for the full 5-day trial period. The majority agreed that IfA lenses delivered consistently clear vision throughout the day (82.1%), including during physical activities (85.7%) and digital device use (87.0%). Additionally, 77.6% reported reduced halos and glare, even in low-light conditions. Ease of handling was rated favorably by 92.8%, and 91.8% gave a positive overall opinion of the lens. Many indicated they would continue wearing IfA lenses after the study (84.6%) and would recommend them to friends or family who wear contact lenses (93.8%). Participants also expressed interest in learning about new contact lens technologies, with 92.8% valuing ECP education and 86.5% wanting updates on comfort-enhancing innovations. Favorable responses exceeded 50% for all key measures (p<0.001).>

CONCLUSIONS: The present study provides patient perspectives on the real-world performance of the IfA CL. Patients agreed it delivered consistently clear vision and reported a highly positive opinion of it overall; they were likely to continue wear after the trial and were likely to recommend to other CL wearers. Patients are also very open to education and discussion regarding new advancements.